Last reviewed · How we verify

Zinc Pyrithione (PYRITHIONE ZINC)

FDA-approved approved Small molecule

Zinc Pyrithione works by inhibiting the activity of a specific potassium channel in the skin, which helps to reduce inflammation and prevent fungal growth.

Zinc Pyrithione, also known as Pyrithione Zinc, is a small molecule drug in the pyrithione zinc class. It targets the Potassium voltage-gated channel subfamily KQT member 2, and is approved for the treatment of Pityriasis simplex and Seborrheic dermatitis. The drug is off-patent, with no active Orange Book patents. It was originally developed by an unknown entity and is currently owned by an unknown entity. As a result, there is limited information available on its pharmacokinetic properties.

At a glance

Generic namePYRITHIONE ZINC
Drug classpyrithione zinc
TargetPotassium voltage-gated channel subfamily KQT member 2
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved
First approval1986

Mechanism of action

Imagine your skin has tiny locks that control how much water and other substances get in and out. Zinc Pyrithione blocks one of these locks, making it harder for fungi and other irritants to cause problems. This helps to calm down the skin and reduce symptoms of conditions like seborrheic dermatitis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: